PharmTech

The Effect of Mill Type on Two Dry-Granulated Placebo Formulations

The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility. The particle-size distribution of a pharmaceutical granulation is ...
PharmTech

Effect of raw materials on the formulation of norfloxacin tablets

Although physicochemical preformulation screening is practised universally within the pharmaceutical industry, physicomechanical screening is applied to a lesser extent and often only where a problem ...
Multiple Sclerosis News Today

Dissolvable film may deliver more MS medicine than standard tablets

Dissolvable film BNT23001 led to about 40% higher cladribine exposure than tablets in a preclinical pig study, BioNxt ...
Monthly Prescribing Reference

New Tablet Formulation of SMA Therapy Evrysdi Gets FDA Approval

Credit: Genentech. The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water. Each Evrysdi tablet contains 5mg of risdiplam and is suitable ...
PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...
Royal Society of Chemistry

Hands-on Tablet Development, including the principles of Pre-formulation, Formulation and Process Development

This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
Monthly Prescribing Reference

Brukinsa Tablets Get FDA Nod for All Approved Indications

The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...
Business Wire

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA

BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
Cure Today

FDA Approves Brukinsa Tablet For Various Blood Cancers

The FDA approved a new tablet formulation of Brukinsa for five cancer indications, simplifying dosing to two 160 mg tablets daily. Brukinsa is the only BTK inhibitor offering flexible dosing and ...
AFP

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of ...
PMLiVE

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...